Access the full text.
Sign up today, get DeepDyve free for 14 days.
M. Majem, J. Goldman, T. John, C. Grohé, K. Laktionov, Sang-We Kim, T. Kato, H. Vu, Shun Lu, Shanqing Li, K. Lee, C. Akewanlop, Chong-Jen Yu, F. Marinis, L. Bonanno, M. Dómine, F. Shepherd, S. Atagi, L. Zeng, Dakshayini Kulkarni, N. Medic, M. Tsuboi, R. Herbst, Yi-long Wu (2022)Health-Related Quality of Life Outcomes in Patients with Resected Epidermal Growth Factor Receptor–Mutated Non–Small Cell Lung Cancer Who Received Adjuvant Osimertinib in the Phase III ADAURA Trial
Clinical Cancer Research, 28
Yuelun Zhang, Jin-Qiu Yuan, K. Wang, Xiao-Hong Fu, Xiaoran Han, D. Threapleton, Zuyao Yang, C. Mao, Jinling Tang (2016)The prevalence of EGFR mutation in patients with non-small cell lung cancer: a systematic review and meta-analysis
Sreenath Sharma, D. Bell, J. Settleman, D. Haber (2007)Epidermal growth factor receptor mutations in lung cancer
Nature Reviews Cancer, 7
M Tsuboi, W Weder, C Escriu, C Blakely, J He, S Dacic (2021)Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA
Future Med, 17
P. Cagle, T. Allen, R. Olsen (2013)Lung cancer biomarkers: present status and future developments.
Archives of pathology & laboratory medicine, 137 9
T. Reungwetwattana, K. Nakagawa, B. Cho, M. Cobo, E. Cho, A. Bertolini, S. Bohnet, Caicun Zhou, K. Lee, N. Nogami, I. Okamoto, N. Leighl, R. Hodge, A. McKeown, Andrew Brown, Y. Rukazenkov, S. Ramalingam, J. Vansteenkiste (2018)CNS Response to Osimertinib Versus Standard Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Patients With Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Jianxing He, C. Su, W. Liang, Shidong Xu, Lin Wu, Xiangning Fu, Xiaodong Zhang, D. Ge, Qun Chen, W. Mao, Lin Xu, Chun Chen, Bing Hu, G. Shao, Jian Hu, Jian Zhao, Xiaoqing Liu, Zhidong Liu, Zheng Wang, Ze-min Xiao, Taiqian Gong, Wen-zhao Lin, Xingya Li, F. Ye, Yang Liu, Haitao Ma, Yunchao Huang, Jianying Zhou, Zhonglin Wang, Junke Fu, L. Ding, L. Mao, Caicun Zhou (2021)Icotinib versus chemotherapy as adjuvant treatment for stage II-IIIA EGFR-mutant non-small-cell lung cancer (EVIDENCE): a randomised, open-label, phase 3 trial.
The Lancet. Respiratory medicine
W. Zhong, Qun Wang, W. Mao, Songtao Xu, Lin Wu, Yi Shen, Yongyu Liu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, K. Fei, Xiao-fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Ke-Neng Chen, Shi-dong Xu, Lunxu Liu, P. Yu, Buhai Wang, Haining Ma, Hong-Hong Yan, Xue-Ning Yang, Qing Zhou, Yi-long Wu (2018)Gefitinib versus vinorelbine plus cisplatin as adjuvant treatment for stage II-IIIA (N1-N2) EGFR-mutant NSCLC (ADJUVANT/CTONG1104): a randomised, open-label, phase 3 study.
The Lancet. Oncology, 19 1
J. Zeng, W. Mao, Qixun Chen, T. Luo, Yi-long Wu, Qing Zhou, Xue-Ning Yang, Hong-Hong Yan, W. Zhong, Qun Wang, Songtao Xu, Lin Wu, Yicong Shen, Yongyu Liu, Chun Chen, Ying Cheng, Lin Xu, Jun Wang, K. Fei, Xiao-fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun-jiang Xu, Ke-Neng Chen, Shi-dong Xu, Lunxu Liu, P. Yu, Buhai Wang, Haining Ma (2020)Quality of life with adjuvant gefitinib versus vinorelbine plus cisplatin in patients with completely resected stage II-IIIA (N1-N2) EGFR-mutant non-small-cell lung cancer: Results from the ADJUVANT (CTONG1104) study.
Lung cancer, 150
M. Tsuboi, W. Weder, C. Escriu, C. Blakely, Jianxing He, S. Dacic, Y. Yatabe, L. Zeng, A. Walding, J. Chaft (2021)Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone for EGFR-mutated resectable non-small-cell lung cancer: NeoADAURA
Future Oncology, 17
M. Tsuboi, Y. Wu, C. Grohé, T. John, M. Tarruella, J. Wang, T. Kato, J. Goldman, S. Kim, C-J. Yu, H. Vu, G. Mukhametshina, C. Akewanlop, F. Marinis, F. Shepherd, D. Urban, M. Stachowiak, A. Bolaños, X. Huang, R. Herbst (2022)LBA47 Osimertinib as adjuvant therapy in patients (pts) with resected EGFR-mutated (EGFRm) stage IB-IIIA non-small cell lung cancer (NSCLC): Updated results from ADAURA
Annals of Oncology
P. Forde, J. Spicer, Shun Lu, M. Provencio, T. Mitsudomi, M. Awad, E. Felip, S. Broderick, J. Brahmer, S. Swanson, K. Kerr, Changli Wang, T. Ciuleanu, G. Saylors, F. Tanaka, H. Ito, Keke Chen, M. Liberman, E. Vokes, J. Taube, C. Dorange, Junliang Cai, J. Fiore, A. Jarkowski, D. Balli, M. Sausen, D. Pandya, C. Calvet, N. Girard (2022)Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer.
The New England journal of medicine
Yi-long Wu, M. Tsuboi, T. John, C. Grohé, M. Majem, J. Goldman, K. Laktionov, Sang-We Kim, T. Kato, H. Vu, Shun Lu, K. Lee, C. Akewanlop, Chong-Jen Yu, F. Marinis, L. Bonanno, M. Dómine, F. Shepherd, L. Zeng, R. Hodge, A. Atasoy, Y. Rukazenkov, R. Herbst (2021)A plain language summary of results from the ADAURA study: osimertinib after surgery for patients who have early-stage EGFR-mutated non-small cell lung cancer.
F. Barlesi, C. Chouaid, J. Crequit, H. Caer, J. Pujol, J. Legodec, A. Vergnenègre, J. Treut, E. Fabre-Guillevin, A. Loundou, P. Auquier, M. Siméoni, P. Thomas (2015)A randomized trial comparing adjuvant chemotherapy with gemcitabine plus cisplatin with docetaxel plus cisplatin in patients with completely resected non-small-cell lung cancer with quality of life as the primary objective.
Interactive cardiovascular and thoracic surgery, 20 6
J. Remon, C. Steuer, S. Ramalingam, E. Felip (2018)Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients
Annals of Oncology, 29
S. Dearden, J. Stevens, Yi-long Wu, D. Blowers (2013)Mutation incidence and coincidence in non small-cell lung cancer: meta-analyses by ethnicity and histology (mutMap)
Annals of Oncology, 24
D. Yue, Shidong Xu, Qun Wang, Xiaofei Li, Yi Shen, Heng Zhao, Chun Chen, W. Mao, Wei Liu, Junfeng Liu, Lanjun Zhang, Haitao Ma, Qiang Li, Yue Yang, Yongyu Liu, Haiquan Chen, Changli Wang (2018)Erlotinib versus vinorelbine plus cisplatin as adjuvant therapy in Chinese patients with stage IIIA EGFR mutation-positive non-small-cell lung cancer (EVAN): a randomised, open-label, phase 2 trial.
The Lancet. Respiratory medicine, 6 11
D. Cross, S. Ashton, S. Ghiorghiu, C. Eberlein, A. Caroline, Nebhan, P. Spitzler, J. Orme, M. Finlay, A. Richard, Ward, M. Mellor, G. Hughes, Amar Rahi, V. Jacobs, M. red, Brewer, E. Ichihara, Jing Sun, Hailing Jin, P. Ballard, Katherine Al-Kadhimi, R. Rowlinson, T. Klinowska, Graham Richmond, M. Cantarini, Dong-Wan Kim, M. Ranson, W. Pao (2014)AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer.
Cancer discovery, 4 9
(2011)User’s manual for the SF-36v2 Health Survey
H. Tada, T. Mitsudomi, T. Misumi, K. Sugio, M. Tsuboi, I. Okamoto, Y. Iwamoto, N. Sakakura, S. Sugawara, S. Atagi, Toshiaki Takahashi, H. Hayashi, M. Okada, H. Inokawa, H. Yoshioka, Kazuhisa Takahashi, M. Higashiyama, I. Yoshino, K. Nakagawa (2021)Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non–Small-Cell Lung Cancer With EGFR Mutation (IMPACT)
Journal of Clinical Oncology, 40
Yi-long Wu, M. Tsuboi, Jie He, T. John, C. Grohé, M. Majem, J. Goldman, K. Laktionov, Sang-We Kim, T. Kato, H. Vu, Shun Lu, K. Lee, C. Akewanlop, Chong-Jen Yu, F. Marinis, L. Bonanno, M. Dómine, F. Shepherd, L. Zeng, R. Hodge, A. Atasoy, Y. Rukazenkov, R. Herbst (2020)Osimertinib in Resected EGFR-Mutated Non-Small-Cell Lung Cancer.
The New England journal of medicine
N. Colclough, Kan Chen, P. Johnström, Nicole Strittmatter, Yumei Yan, G. Wrigley, M. Schou, R. Goodwin, K. Varnäs, S. Adua, Minghui Zhao, D. Nguyen, G. Maglennon, P. Barton, James Atkinson, Lin Zhang, A. Janefeldt, Joanne Wilson, Aaron Smith, A. Takano, R. Arakawa, M. Kondrashov, J. Malmquist, Evgeny Revunov, A. Vázquez-Romero, M. Moein, A. Windhorst, N. Karp, M. Finlay, R. Ward, J. Yates, Paul Smith, L. Farde, Zack Cheng, D. Cross (2020)Preclinical Comparison of the Blood–brain barrier Permeability of Osimertinib with Other EGFR TKIs
Clinical Cancer Research, 27
P. Postmus, K. Kerr, M. Oudkerk, S. Senan, D. Waller, J. Vansteenkiste, C. Escriu, S. Peters (2017)Early and locally advanced non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up.
Annals of oncology : official journal of the European Society for Medical Oncology, 28 suppl_4
S. Burdett (2014)Preoperative chemotherapy for non-small-cell lung cancer: a systematic review and meta-analysis of individual participant data
Lancet (London, England), 383
J. Pignon, H. Tribodet, G. Scagliotti, J. Douillard, F. Shepherd, R. Stephens, A. Dunant, V. Torri, R. Rosell, L. Seymour, S. Spiro, E. Rolland, R. Fossati, D. Aubert, K. Ding, D. Waller, T. Chevalier (2008)Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 21
Yi-long Wu, M. Ahn, M. Garassino, Ji-Youn Han, N. Katakami, H. Kim, R. Hodge, P. Kaur, Andrew Brown, D. Ghiorghiu, V. Papadimitrakopoulou, T. Mok (2018)CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non-Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3).
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 36 26
A. Bezjak, Christopher Lee, K. Ding, M. Brundage, T. Winton, B. Graham, M. Whitehead, David Johnson, R. Livingston, L. Seymour, F. Shepherd (2008)Quality-of-life outcomes for adjuvant chemotherapy in early-stage non-small-cell lung cancer: results from a randomized trial, JBR.10.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 26 31
I. Lemonnier, F. Guillemin, P. Arveux, C. Clément‐Duchêne, M. Velten, M. Woronoff‐Lemsi, D. Jolly, C. Baumann (2014)Quality of life after the initial treatments of non-small cell lung cancer: a persistent predictor for patients’ survival
Health and Quality of Life Outcomes, 12
S. Peters, C. Bexelius, V. Munk, N. Leighl (2016)The impact of brain metastasis on quality of life, resource utilization and survival in patients with non-small-cell lung cancer.
Cancer treatment reviews, 45
Yuankai Shi, J. Au, S. Thongprasert, S. Srinivasan, C. Tsai, M. Khoa, K. Heeroma, Y. Itoh, G. Cornelio, Pan‐Chyr Yang (2014)A Prospective, Molecular Epidemiology Study of EGFR Mutations in Asian Patients with Advanced Non–Small-Cell Lung Cancer of Adenocarcinoma Histology (PIONEER)
Journal of Thoracic Oncology, 9
Wenhui Zhong, Qun Wang, W. Mao, Songtao Xu, Lin Wu, Yu-cheng Wei, Yongyu Liu, Chun Chen, Ying Cheng, R. Yin, Fan Yang, S. Ren, Xiao-fei Li, Jian Li, Cheng Huang, Zhidong Liu, Shun Xu, Ke-Neng Chen, Shi-dong Xu, Lunxu Liu, P. Yu, Buhai Wang, Haining Ma, Jin-Ji Yang, Hong-Hong Yan, Xue-Ning Yang, S. Liu, Qing Zhou, Yi-long Wu (2020)Gefitinib Versus Vinorelbine Plus Cisplatin as Adjuvant Treatment for Stage II-IIIA (N1-N2) EGFR-Mutant NSCLC: Final Overall Survival Analysis of CTONG1104 Phase III Trial
Journal of Clinical Oncology, 39
S. Burdett, L. Stewart, L. Rydzewska (2006)A Systematic Review and Meta-analysis of the Literature: Chemotherapy and Surgery versus Surgery Alone in Non-small Cell Lung Cancer
Journal of Thoracic Oncology, 1
K. Kelly, N. Altorki, W. Eberhardt, M. O'Brien, D. Spigel, L. Crinò, C. Tsai, Joo‐Hang Kim, E. Cho, P. Hoffman, S. Orlov, P. Serwatowski, Jiuzhou Wang, M. Foley, J. Horan, F. Shepherd (2015)Adjuvant Erlotinib Versus Placebo in Patients With Stage IB-IIIA Non-Small-Cell Lung Cancer (RADIANT): A Randomized, Double-Blind, Phase III Trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 33 34
Targeted Oncology https://doi.org/10.1007/s11523-022-00927-5 COMMENTAR Y Current and Future Perspectives of Health‑Related Quality of Life in Resectable EGFR‑Mutated Non‑Small Cell Lung Cancer: A Podcast 1 2 3 4 Thomas John · Margarita Majem · Diane Legg · Jonathan Goldman Accepted: 25 October 2022 © The Author(s) 2022 Transcript before or after surgery can improve our ability to prevent the cancer from coming back. Most patients will proceed to sur- TJ: Thomas John (medical oncologist; lead presenter) gery first and then get after surgery post-operative or some- JG: Jonathan Goldman (medical oncologist) times called ‘adjuvant’ chemotherapy, usually with two drugs MM: Margarita Majem (medical oncologist) called a platinum-based chemotherapy for stages II and up to DL: Diane Legg (patient advocate) IIIA . There are increasingly the utilization of pre-operative or neoadjuvant chemotherapy, especially chemotherapy with TJ: Hello. Welcome to this podcast on health-related immunotherapy, for some patients [2–4]. However, for many, quality of life in resectable EGFR-mutant non-small cell the standard remains surgery followed by chemotherapy . lung cancer current and future perspectives. My name is Despite some significant advances, the outcomes remain poor Thomas John, I’m a medical oncologist and researcher at the [3–5] and there is significant and important research underway Department of Medical Oncology, Peter MacCallum Can-
Targeted Oncology – Springer Journals
Published: Jan 1, 2023
Access the full text.
Sign up today, get DeepDyve free for 14 days.